Last 35 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -21.00 | — | — | 3.98 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1808.82 | 1794.26 | 2176.52 | 1371.03 | 938.89 | 864.47 | 139.56 | 143.99 | 107.90 | 118.87 | 220.24 | 25.77 | 14.45 | 11.86 | 25.32 | 5.10 | 17.81 | — | — | — | — |
| — | +107.6% | +1459.5% | +852.2% | +770.2% | +627.3% | -36.6% | +458.7% | +646.7% | +902.0% | +769.8% | +405.7% | -18.9% | — | — | — | — | — | — | — | — | |
| P/B Ratio | 6.76 | 4.66 | 3.36 | 3.16 | 2.72 | 2.20 | 1.98 | 2.17 | 2.77 | 2.47 | 2.07 | 0.28 | 0.30 | 0.62 | 0.62 | 0.33 | 0.67 | 0.52 | 1.13 | 1.51 | 2.25 |
| — | +111.6% | +69.8% | +45.7% | -1.9% | -11.0% | -4.4% | +676.6% | +826.6% | +301.2% | +231.9% | -14.2% | -55.6% | +18.5% | -44.8% | -78.4% | -70.0% | -79.9% | -74.7% | -43.0% | +8.6% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | 8.13 | — | — | — | 1.27 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | +539.1% | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 3.85 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 83.6% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 97.9% | 91.3% | 100.0% | 95.8% | 100.0% | — | — | — | — |
| — | 0.0% | -16.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +2.1% | +9.5% | 0.0% | +4.4% | -2.1% | — | — | — | — | — | — | — | — | |
| Operating Margin | -8739.3% | -8079.1% | -10050.3% | -24486.3% | -10173.7% | -18096.9% | -2852.7% | -2406.9% | -1376.6% | -1191.8% | -2041.6% | -2835.0% | -1705.5% | -1215.3% | -1614.1% | -910.0% | -703.7% | — | — | — | — |
| — | +55.4% | -252.3% | -917.3% | -639.0% | -1418.4% | -39.7% | +15.1% | +19.3% | +1.9% | -26.5% | -211.5% | -142.4% | — | — | — | — | — | — | — | — | |
| Net Margin | -7973.3% | -6598.6% | -8819.4% | 34473.6% | -9284.1% | -16388.1% | -2537.5% | -2144.8% | -1159.0% | -945.1% | -1573.0% | -2311.4% | -1597.7% | -1149.6% | -1489.3% | -860.9% | -663.6% | — | — | — | — |
| — | +59.7% | -247.6% | +1707.3% | -701.0% | -1634.0% | -61.3% | +7.2% | +27.5% | +17.8% | -5.6% | -168.5% | -140.8% | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -38.4% | -4.2% | -4.8% | 18.8% | -8.7% | -10.0% | -8.7% | -8.2% | -7.2% | -4.8% | -5.1% | -6.1% | -11.7% | -14.7% | -9.4% | -10.2% | -6.0% | -12.0% | -14.2% | -10.6% | -8.9% |
| — | +57.7% | +44.4% | +328.6% | -19.7% | -107.9% | -70.7% | -35.4% | +38.0% | +67.1% | +45.9% | +40.6% | -94.7% | -21.7% | +33.8% | +3.9% | +32.5% | -18.1% | -10.6% | +11.4% | +16.5% | |
| ROA | -35.9% | -4.1% | -4.6% | 17.7% | -8.1% | -9.4% | -8.2% | -7.8% | -7.0% | -4.7% | -4.9% | -5.7% | -10.9% | -13.7% | -8.5% | -8.2% | -4.6% | -9.3% | -11.9% | -9.7% | -8.2% |
| — | +56.5% | +43.8% | +326.2% | -16.9% | -100.1% | -66.9% | -37.5% | +36.1% | +65.9% | +42.5% | +30.6% | -137.3% | -47.0% | +28.7% | +16.0% | +43.8% | -0.8% | -4.6% | +9.9% | +15.6% | |
| ROIC | -34.4% | -5.6% | -6.9% | -11.2% | -7.7% | -8.6% | -7.6% | -7.5% | -12.9% | -37.9% | -33.2% | -33.0% | -70.1% | -45.1% | -13.4% | -10.4% | -5.9% | -12.1% | -23.4% | -41.3% | -34.2% |
| — | +34.3% | +10.4% | -48.1% | +39.9% | +77.4% | +77.0% | +77.2% | +81.7% | +16.1% | -148.5% | -218.6% | -1078.4% | -273.2% | +42.9% | +74.9% | +82.6% | +41.6% | -38.1% | -48.2% | +32.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.01 | 0.25 | 0.23 | 0.21 | — | — |
| — | -75.0% | -73.3% | -33.6% | +155.7% | +286.3% | +218.4% | +22.1% | -75.5% | — | — | -67.6% | -98.5% | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 13.32 | 26.10 | 29.25 | 13.32 | 17.35 | 13.12 | 15.99 | 15.22 | 18.30 | 36.46 | 42.52 | 18.42 | 14.64 | 19.49 | 13.95 | 9.97 | 10.22 | 12.62 | 11.37 | 16.63 | 19.36 |
| — | +98.9% | +83.0% | -12.5% | -5.2% | -64.0% | -62.4% | -17.4% | +25.0% | +87.0% | +204.8% | +84.7% | +43.2% | +54.5% | +22.7% | -40.0% | -47.2% | -33.5% | -22.5% | +25.5% | +16.3% | |
| Quick Ratio | 13.32 | 26.10 | 29.25 | 13.32 | 17.35 | 13.12 | 15.99 | 15.22 | 18.30 | 36.23 | 42.52 | 18.42 | 14.64 | 19.49 | 13.95 | 9.97 | 10.22 | 12.62 | 11.37 | 16.63 | 19.36 |
| — | +98.9% | +83.0% | -12.5% | -5.2% | -63.8% | -62.4% | -17.4% | +25.0% | +85.9% | +204.8% | +84.7% | +43.2% | +54.5% | +22.7% | -40.0% | -47.2% | -33.5% | -22.5% | +25.5% | +16.3% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -21.27 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 35 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DNTH stock.
Dianthus Therapeutics, Inc.'s current P/E is -21.0x. The average P/E over the last 1 quarters is 4.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Dianthus Therapeutics, Inc.'s current operating margin is -8739.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Dianthus Therapeutics, Inc.'s business trajectory between earnings reports.